{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:28:54Z","timestamp":1752229734333,"version":"3.41.0"},"reference-count":95,"publisher":"Informa UK Limited","issue":"2","funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychoactive Drugs"],"published-print":{"date-parts":[[2025,3,15]]},"DOI":"10.1080\/02791072.2024.2314220","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T12:42:55Z","timestamp":1707396175000},"page":"137-148","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Direct-To-Definitive Urine and Oral Fluid Test Results for Unscreened and Rarely Screened Drugs in Individuals Applying for Methadone Treatment in 7 U.S. States"],"prefix":"10.1080","volume":"57","author":[{"given":"Miranda J.","family":"Lee-Easton","sequence":"first","affiliation":[{"name":"The Evaluation Center at Western Michigan University","place":["Kalamazoo, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Magura","sequence":"additional","affiliation":[{"name":"The Evaluation Center at Western Michigan University","place":["Kalamazoo, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruqayyah","family":"Abu-Obaid","sequence":"additional","affiliation":[{"name":"The Evaluation Center at Western Michigan University","place":["Kalamazoo, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pete","family":"Reed","sequence":"additional","affiliation":[{"name":"Forensic Fluids Laboratories","place":["Kalamazoo, MI, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandi","family":"Allgaier","sequence":"additional","affiliation":[{"name":"Forensic Fluids Laboratories","place":["Kalamazoo, MI, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Fish","sequence":"additional","affiliation":[{"name":"Forensic Fluids Laboratories","place":["Kalamazoo, MI, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Maletta","sequence":"additional","affiliation":[{"name":"Forensic Fluids Laboratories","place":["Kalamazoo, MI, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyadarsha","family":"Amaratunga","sequence":"additional","affiliation":[{"name":"Forensic Fluids Laboratories","place":["Kalamazoo, MI, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bridget","family":"Lorenz-Lemberg","sequence":"additional","affiliation":[{"name":"Forensic Fluids Laboratories","place":["Kalamazoo, MI, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Levitas","sequence":"additional","affiliation":[{"name":"Forensic Fluids Laboratories","place":["Kalamazoo, MI, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EricD","family":"Achtyes","sequence":"additional","affiliation":[{"name":"Western Michigan University","place":["Kalamazoo, MI, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"e_1_3_6_2_1","unstructured":"Addiction Center. 2023. Remeron addiction and abuse. Accessed August 17 2023. https:\/\/www.addictioncenter.com\/stimulants\/antidepressants\/remeron-addiction-abuse\/."},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.7759\/CUREUS.36189"},{"key":"e_1_3_6_4_1","unstructured":"Alcohol and drug foundation. 2022. New psychoactive substances. Accessed November 6 2023. https:\/\/adf.org.au\/drug-facts\/new-psychoactive-substances\/."},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2011.011116"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JSPS.2022.10.010"},{"key":"e_1_3_6_7_1","unstructured":"American Society of Addiction Medicine. 2023. Appropriate use of drug testing in clinical addiction medicine. https:\/\/www.asam.org\/docs\/default-source\/quality- science\/2017_4_5_appropriate-use-of-drug-testing-in-clinical-addiction-medicine- document.pdf?sfvrsn=4hild Trends. https:\/\/www.childtrends.org\/indicators\/child- maltreatment\/2017."},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/J.1365-2044.2003.03154_18.X"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408444.2018.1553935"},{"key":"e_1_3_6_10_1","unstructured":"Better Addiction Care. 2023. Understanding hydroxyzine overdose and addiction. Accessed August 15 2023. https:\/\/betteraddictioncare.com\/drugs\/hydroxyzine\/."},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666150619092236"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-813776-5.00014-5"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2020.1802087"},{"key":"e_1_3_6_14_1","unstructured":"Carlson K. 2023. Exhaustive list of kratom drug interactions: 260+ medications. Accessed August 21 2023. https:\/\/kratom.org\/interactions\/."},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15050565"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ptdy.2021.09.016"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/JAT\/26.8.541"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00569"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/S11419-021-00596-5"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010375727768"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/JAT\/BKZ048"},{"key":"e_1_3_6_22_1","unstructured":"Drugs.com. 2023a. Drug interaction checker - for drugs food and alcohol. Accessed August 14 2023. https:\/\/www.drugs.com\/drug_interactions.html."},{"key":"e_1_3_6_23_1","unstructured":"Drugs.com. 2023b. Ephedrine: Uses dosage & side Effects. Accessed August 15 2023. https:\/\/www.drugs.com\/ephedrine.html."},{"key":"e_1_3_6_24_1","unstructured":"Drugs.com. 2023c. Gabapentin. Accessed August 16 2023. https:\/\/www.drugs.com\/gabapentin.html."},{"key":"e_1_3_6_25_1","unstructured":"Drugs.com. 2023d. Hydroxyzine: 7 things you should know. Accessed August 24 2023. https:\/\/www.drugs.com\/tips\/hydroxyzine-patient-tips."},{"key":"e_1_3_6_26_1","unstructured":"Drugs.com. 2023e. Kratom. Accessed August 21 2023. https:\/\/www.drugs.com\/npp\/kratom.html."},{"key":"e_1_3_6_27_1","unstructured":"Drugs.com. 2023f. Trazodone. Accessed August 21 2023. https:\/\/www.drugs.com\/search.php?searchterm=trazodone."},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBR.2020.112796"},{"key":"e_1_3_6_29_1","unstructured":"Erickson M. 2023. Common opioids less effective for patients on SSRI antidepressants. Accessed August 16 2023. https:\/\/med.stanford.edu\/news\/all-news\/2019\/02\/common-opioids-less-effective-for-patients-on-ssri-antidepressants.html."},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.9740\/MHC.2023.04.025"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/JCPH.1833"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.3892\/BR.2017.901"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.36076\/ppj.2018.6.e583"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PMED.1002396"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/AJAD.12866"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006815.pub2"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CHC.2016.02.005"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/JAT\/BKR019"},{"key":"e_1_3_6_39_1","unstructured":"Huecker M. R. A. Smiley and A. Saadabadi 2023. Bupropion. Accessed August 17 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470212\/."},{"key":"e_1_3_6_40_1","unstructured":"Immunalysis. 2023. Quantisal. Accessed June 18 2023 https:\/\/immunalysis.com\/products\/oral-fluid\/quantisal\/."},{"key":"e_1_3_6_41_1","unstructured":"Jilani T. J. R. Gibbons R. M. Faizy and A. Saadabadi 2023. Mirtazapine. Accessed August 17 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519059\/."},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/AJHP\/ZXAB486"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.5811\/WESTJEM.2016.10.32322"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/PDS.4771"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408363.2017.1385053"},{"key":"e_1_3_6_46_1","unstructured":"Maan J. S. M. Ershadi I. Khan and A. Saadabadi 2023. Quetiapine. Accessed August 24 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459145\/."},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.DRUGALCDEP.2023.110894"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.15585\/MMWR.MM7119A3"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.15585\/MMWR.MM7006A4"},{"key":"e_1_3_6_50_1","unstructured":"Mayo Clinic. 2023a. Drugs and supplements: Citalopram. Accessed August 16 2023. https:\/\/www.mayoclinic.org\/drugs-supplements\/citalopram-oral-route\/description\/drg-20062980."},{"key":"e_1_3_6_51_1","unstructured":"Mayo Clinic. 2023b. Drugs and supplements: Ephedrine. Accessed August 15 2023. https:\/\/www.mayoclinic.org\/drugs-supplements\/ephedrine-intravenous-route\/description\/drg-20406071."},{"key":"e_1_3_6_52_1","unstructured":"Mayo Clinic. 2023c. Drugs and supplements: Hydroxyzine (oral route). Accessed August 15 2023. https:\/\/www.mayoclinic.org\/drugs-supplements\/hydroxyzine-oral-route\/side-effects\/drg-20311434?p=1."},{"key":"e_1_3_6_53_1","unstructured":"Mayo Clinic. 2023d. Kratom: Unsafe and ineffective. Accessed August 21 2023. https:\/\/www.mayoclinic.org\/healthy-lifestyle\/consumer-health\/in-depth\/kratom\/art-20402171."},{"key":"e_1_3_6_54_1","unstructured":"Medicines and Healthcare Products Regulatory Agency United Kingdom. 2023. Suspected drug interaction between citalopram and cocaine. Accessed August 16 2023. https:\/\/www.gov.uk\/drug-safety-update\/citalopram-suspected-drug-interaction-with-cocaine-prescribers-should-consider-enquiring-about-illicit-drug-use."},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1373\/JALM.2017.023010"},{"key":"e_1_3_6_56_1","unstructured":"Miller L. A. Sharp and S. Thomas 2023. Neurontin (gabapentin) addiction: Effects symptoms & treatment. American Addiction Centers. https:\/\/americanaddictioncenters.org\/neurontin-abuse."},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.5055\/JOM.2015.0254"},{"key":"e_1_3_6_58_1","unstructured":"National Alliance on Mental Illness. 2023. Hydroxyzine (vistaril). Accessed August 15 2023. https:\/\/www.nami.org\/About-Mental-Illness\/Treatments\/Mental-Health-Medications\/Types-of-Medication\/Hydroxyzine-(Vistaril)."},{"key":"e_1_3_6_59_1","unstructured":"National Health Service - United Kingdom. (2023). Chlorphenamine: Drowsy (sedating) antihistamine - NHS. Accessed August 14 2023. https:\/\/www.nhs.uk\/medicines\/chlorphenamine-including-piriton\/."},{"key":"e_1_3_6_60_1","unstructured":"National Library of Medicine. 2022. Drug Testing. Accessed November 3 2023. https:\/\/medlineplus.gov\/lab-tests\/drug-testing\/."},{"key":"e_1_3_6_61_1","unstructured":"National Library of Medicine. 2023a. Citalopram. Accessed August 24 2023. https:\/\/medlineplus.gov\/druginfo\/meds\/a699001.html."},{"key":"e_1_3_6_62_1","unstructured":"National Library of Medicine. 2023b. Hydroxyzine: MedlinePlus Drug Information. Accessed August 15 2023. https:\/\/medlineplus.gov\/druginfo\/meds\/a682866.html."},{"key":"e_1_3_6_63_1","unstructured":"National Library of Medicine. 2023c. Pregabalin. Accessed August 17 2023. https:\/\/medlineplus.gov\/druginfo\/meds\/a605045.html."},{"key":"e_1_3_6_64_1","unstructured":"National Library of Medicine. 2023d. Trazodone. Accessed August 24 2023. https:\/\/medlineplus.gov\/druginfo\/meds\/a681038.html."},{"issue":"8","key":"e_1_3_6_65_1","first-page":"662","article-title":"Clonidine, gabapentin, and some SSRIs effective for hot flashes","volume":"55","author":"Nelson H. D.","year":"2006","unstructured":"Nelson, H. D., K. Vesco, and E. Haney. 2006. Clonidine, gabapentin, and some SSRIs effective for hot flashes. The Journal of Family Practice 55 (8):662. https:\/\/www.scopus.com\/inward\/record.uri?eid=2-s2.0-33750730267&partnerID=40&md5=9c94fa1683c210a96f4af4eebafb7fe0.","journal-title":"The Journal of Family Practice"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/S11845-019-02106-4"},{"key":"e_1_3_6_67_1","unstructured":"Office of Justice Programs. 2023. Death over-the-counter: Dangers of ephedrine. Accessed August 15 2023. https:\/\/ojp.gov\/ncjrs\/virtual-library\/abstracts\/death-over-counter-dangers-ephedrine."},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.46079"},{"key":"e_1_3_6_69_1","unstructured":"Perananthan V. and N. A. Buckley 2023. Opioids and antidepressants: Which combinations to avoid. Accessed August 17 2023. https:\/\/www.nps.org.au\/australian-prescriber\/articles\/opioids-and-antidepressants-which-combinations-to-avoid#article."},{"key":"e_1_3_6_70_1","unstructured":"Premier Biotech. 2022. Urine versus oral fluid testing - Let\u2019s compare. Accessed November 6 2023. https:\/\/premierbiotech.com\/innovation\/lets-compare\/."},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S124391"},{"key":"e_1_3_6_72_1","unstructured":"Relias Media. (2023). Behind the banning of ephedra: Misuse abuse and dangers. Accessed August 15 2023 https:\/\/www.reliasmedia.com\/articles\/6774-behind-the-banning-of-ephedra-misuse-abuse-and-dangers."},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnab303"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199001000-00010"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.7.7.841"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0164-4"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/ADD.15082"},{"key":"e_1_3_6_78_1","unstructured":"Shoar N. S. K. A. Fariba and R. K. Padhy (2023). Citalopram. Accessed August 24 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482222\/."},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.9740\/MHC.2022.06.199"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.DRUGALCDEP.2018.01.018"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/ADD.13324"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP12X653516"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JSAT.2019.12.007"},{"key":"e_1_3_6_84_1","unstructured":"Strum J. 2023. Clonidine abuse and addiction treatment. Accessed August 17 2023. https:\/\/www.orlandorecovery.com\/drug-addiction-resources\/clonidine-abuse\/."},{"key":"e_1_3_6_85_1","unstructured":"Substance Abuse and Mental Health Services Administration. 2012. Clinical drug testing in primary care (technical assistance publication (TAP) 32 No. (SMA) 12-4668). Rockville MD."},{"key":"e_1_3_6_86_1","unstructured":"Sundjaja J. H. R. Shrestha and K. Krishan 2023. McNemar and Mann-Whitney U tests. Accessed November 3 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560699\/."},{"key":"e_1_3_6_87_1","unstructured":"Ulrich A. 2023. 6 pregabalin interactions to watch out for. Accessed August 17 2023. https:\/\/www.goodrx.com\/pregabalin\/interactions."},{"key":"e_1_3_6_88_1","unstructured":"United Nations Office on Drugs and Crime. 2023. UNODC early warning advisory on new psychoactive substances. Accessed November 6 2023. https:\/\/www.unodc.org\/LSS\/Page\/NPS."},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2020.3940"},{"key":"e_1_3_6_90_1","unstructured":"U.S. Food and Drug Administration. 2016. FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjm7-ruwvWAAxVhj4kEHZ79BQsQFnoECCgQAQ&url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F99761%2Fdownload&usg=AOvVaw339z-mANj48PAosZGq2Car&opi=89978449."},{"key":"e_1_3_6_91_1","unstructured":"U.S. Food and Drug Administration. 2020. Neurontin (gabapentin). Accessed August 16 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020235s064_020882s047_021129s046lbl.pdf."},{"key":"e_1_3_6_92_1","unstructured":"Verstraete A. G. and T. Mukhdomi 2023. Clinical drug testing. Accessed August 28 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557523\/."},{"key":"e_1_3_6_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.DRUGALCDEP.2019.107709"},{"key":"e_1_3_6_94_1","unstructured":"World\u2019s Best Rehab. (2023). Mixing chlorpheniramine maleate and cocaine. Accessed August 14 2023. https:\/\/www.worldsbest.rehab\/chlorpheniramine-maleate-and-cocaine\/."},{"key":"e_1_3_6_95_1","unstructured":"Yasaei R. and A. Saadabadi (2023). Clonidine. Accessed August 17 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459124\/."},{"key":"e_1_3_6_96_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2017.00110"}],"container-title":["Journal of Psychoactive Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/02791072.2024.2314220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T05:56:20Z","timestamp":1749102980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02791072.2024.2314220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,15]]}},"alternative-id":["10.1080\/02791072.2024.2314220"],"URL":"https:\/\/doi.org\/10.1080\/02791072.2024.2314220","relation":{},"ISSN":["0279-1072","2159-9777"],"issn-type":[{"type":"print","value":"0279-1072"},{"type":"electronic","value":"2159-9777"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ujpd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ujpd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}